secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001437749-25-018972
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Pharmaceuticals enters into ATM sales agreement for up to $50M common stock offering
--------------------------------------------------------------------------------

- On May 30, 2025, Reviva entered an ATM agreement with B. Riley Securities and Alliance Global Partners to sell up to $50M of common stock.
- Sales will be made through Nasdaq as an 'at the market offering' under Rule 415; agents receive 3% commission.
- Shares issued under effective shelf registration statement (Form S-3 filed Feb 2024).
- No obligation for agents to sell any specific amount; they use commercially reasonable efforts based on company instructions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925018972/0001437749-25-018972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925018972/rvph20250513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-018972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer